Your browser doesn't support javascript.
loading
Hepatitis C virus non-structural proteins modulate cellular kinases for increased cytoplasmic abundance of host factor HuR and facilitate viral replication.
Raheja, Harsha; George, Biju; Tripathi, Sachin Kumar; Saha, Sandhini; Maiti, Tushar Kanti; Das, Saumitra.
Afiliación
  • Raheja H; Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
  • George B; Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
  • Tripathi SK; Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
  • Saha S; Regional Centre for Biotechnology, Faridabad, India.
  • Maiti TK; Regional Centre for Biotechnology, Faridabad, India.
  • Das S; Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
PLoS Pathog ; 19(8): e1011552, 2023 08.
Article en En | MEDLINE | ID: mdl-37540723
ABSTRACT
Host protein HuR translocation from nucleus to cytoplasm following infection is crucial for the life cycle of several RNA viruses including hepatitis C virus (HCV), a major causative agent of hepatocellular carcinoma. HuR assists the assembly of replication-complex on the viral-3'UTR, and its depletion hampers viral replication. Although cytoplasmic HuR is crucial for HCV replication, little is known about how the virus orchestrates the mobilization of HuR into the cytoplasm from the nucleus. We show that two viral proteins, NS3 and NS5A, act co-ordinately to alter the equilibrium of the nucleo-cytoplasmic movement of HuR. NS3 activates protein kinase C (PKC)-δ, which in-turn phosphorylates HuR on S318 residue, triggering its export to the cytoplasm. NS5A inactivates AMP-activated kinase (AMPK) resulting in diminished nuclear import of HuR through blockade of AMPK-mediated phosphorylation and acetylation of importin-α1. Cytoplasmic retention or entry of HuR can be reversed by an AMPK activator or a PKC-δ inhibitor. Our findings suggest that efforts should be made to develop inhibitors of PKC-δ and activators of AMPK, either separately or in combination, to inhibit HCV infection.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hepatitis C / Hepacivirus Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2023 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hepatitis C / Hepacivirus Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2023 Tipo del documento: Article País de afiliación: India